• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Adjuvant tamoxifen: how long before we know how long?辅助性他莫昔芬：我们要多久才能知道使用时长？
BMJ. 1998 May 16;316(7143):1518-9. doi: 10.1136/bmj.316.7143.1518.
2
Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.完全切除原位导管癌女性患者的放疗与他莫昔芬治疗
Lancet. 2003 Oct 4;362(9390):1156-7. doi: 10.1016/s0140-6736(03)14479-0.
3
Extended adjuvant therapy with letrozole: reducing the risk of recurrence.来曲唑延长辅助治疗：降低复发风险
Expert Rev Anticancer Ther. 2006 Jun;6(6):849-59. doi: 10.1586/14737140.6.6.849.
4
Tamoxifen versus toremifene in the adjuvant treatment of breast cancer.他莫昔芬与托瑞米芬在乳腺癌辅助治疗中的比较
Eur J Cancer. 2002 Nov;38 Suppl 6:S37-8. doi: 10.1016/s0959-8049(02)00279-4.
5
Long term adjuvant therapy for primary breast cancer.原发性乳腺癌的长期辅助治疗。
BMJ. 1996 Feb 17;312(7028):389-90. doi: 10.1136/bmj.312.7028.389.
6
Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.回复：1975 - 1999年美国乳腺癌辅助多药化疗和他莫昔芬的使用趋势
J Natl Cancer Inst. 2003 May 7;95(9):683; author reply 684-5. doi: 10.1093/jnci/95.9.683.
7
The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?早期乳腺癌辅助内分泌治疗的最佳持续时间——用什么药物以及多长时间？
Curr Oncol Rep. 2014;16(1):358. doi: 10.1007/s11912-013-0358-9.
8
Breast cancer: new aspects of adjuvant hormonal therapy.
Ann Oncol. 2000;11 Suppl 3:13-25. doi: 10.1093/annonc/11.suppl_3.13.
9
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.乳腺癌激素受体及其他因素与辅助他莫昔芬疗效的相关性：随机试验的患者水平荟萃分析。
Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.
10
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.早期乳腺癌化疗和激素治疗对复发及15年生存率的影响：随机试验综述
Lancet. 2005;365(9472):1687-717. doi: 10.1016/S0140-6736(05)66544-0.

引用本文的文献

1
Potential anti-genotoxic effect of sodium butyrate to modulate induction of DNA damage by tamoxifen citrate in rat bone marrow cells.丁酸钠对柠檬酸他莫昔芬诱导大鼠骨髓细胞DNA损伤的潜在抗基因毒性作用。
Cytotechnology. 2017 Feb;69(1):89-102. doi: 10.1007/s10616-016-0039-2. Epub 2016 Nov 30.
2
Gynaecological effects of tamoxifen.他莫昔芬的妇科效应
J Clin Pathol. 1999 Feb;52(2):83-8. doi: 10.1136/jcp.52.2.83.
3
More large trials needed to decide best duration of treatment with tamoxifen.需要更多大型试验来确定他莫昔芬的最佳治疗持续时间。
BMJ. 1998 Nov 28;317(7171):1524. doi: 10.1136/bmj.317.7171.1524.

本文引用的文献

1
Postmastectomy radiotherapy in patients with breast cancer - Authors' reply.乳腺癌患者乳房切除术后放疗——作者回复
Lancet. 2014 Nov 22;384(9957):1846-1847. doi: 10.1016/S0140-6736(14)62240-6. Epub 2014 Nov 21.
2
Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group.癌症研究运动试验的初步结果，该试验评估了50岁及以上乳腺癌女性服用他莫昔芬的时长。癌症研究运动乳腺癌试验组当前试验工作组。
J Natl Cancer Inst. 1996 Dec 18;88(24):1834-9. doi: 10.1093/jnci/88.24.1834.
3
Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.淋巴结阳性乳腺癌患者化疗后辅助他莫昔芬治疗超过五年。东部肿瘤协作组。
J Natl Cancer Inst. 1996 Dec 18;88(24):1828-33. doi: 10.1093/jnci/88.24.1828.
4
Five years of tamoxifen--or more?
J Natl Cancer Inst. 1996 Dec 18;88(24):1791-3. doi: 10.1093/jnci/88.24.1791.
5
Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.绝经后早期乳腺癌辅助他莫昔芬治疗两年与五年的随机试验。瑞典乳腺癌协作组
J Natl Cancer Inst. 1996 Nov 6;88(21):1543-9. doi: 10.1093/jnci/88.21.1543.
6
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.针对淋巴结阴性且雌激素受体阳性肿瘤的乳腺癌患者，他莫昔芬治疗五年与五年以上的对比。
J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42. doi: 10.1093/jnci/88.21.1529.
7
Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.可手术乳腺癌辅助他莫昔芬5年与持续治疗的随机对照研究。苏格兰癌症试验乳腺癌研究组。
Br J Cancer. 1996 Jul;74(2):297-9. doi: 10.1038/bjc.1996.356.
8
Sudden fall in breast cancer death rates in England and Wales.英格兰和威尔士乳腺癌死亡率突然下降。
Lancet. 1995 Jun 24;345(8965):1642-3. doi: 10.1016/s0140-6736(95)90151-5.
9
Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years.接受辅助性他莫昔芬治疗至少两年的乳腺癌女性的骨矿物质密度
Breast Cancer Res Treat. 1988 Dec;12(3):297-302. doi: 10.1007/BF01811242.
10
Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.苏格兰他莫昔芬辅助治疗试验中的致命性心肌梗死。苏格兰乳腺癌委员会。
BMJ. 1991 Aug 24;303(6800):435-7. doi: 10.1136/bmj.303.6800.435.

Adjuvant tamoxifen: how long before we know how long?

作者信息

Rea D, Poole C, Gray R

机构信息

Cancer Research Council Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TA.

出版信息

BMJ. 1998 May 16;316(7143):1518-9. doi: 10.1136/bmj.316.7143.1518.

DOI:10.1136/bmj.316.7143.1518
PMID:9582148
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1113163/
Abstract
摘要